Subject: FW: Update on Pfizer/BioNTech
From: Tamar Gabunia <[email-masked]>
To: "[email-masked]" <[email-masked]>, Ekaterine Tikaradze <[email-masked]>
Date: Tue, 23 Feb 2021 15:07:40 +0000

fyi

From: Rosie Grieves (Consultant) [mailto:[email-masked]]
Sent: 22 February, 2021 21:32
To: Tamar Gabunia
Cc: Maia Nikoleishvili ; Natia Khmaladze ; Alexander Khvtisiashvili ; [email-masked]; [email-masked]; Santiago Cornejo ; Sam Muller ; Pascal Bijleveld ; Hannah Kettler (Consultant) ; Katherine Hudak ; Dorcas Noertoft ; Liu, Alvin HL ; Akande, Michelle ; Sousa, Patricia
Subject: Update on Pfizer/BioNTech

Dear Tamar,

I am writing to share an update on the initial limited volume of the COVID-19 vaccine requiring ultra-cold chain produced by Pfizer/BioNTech. After several conversations with Pfizer over the last three weeks, we can now provide more information for your planning purposes.  Thank you for your patience as we have worked through these issues.

Key next steps are outlined in the letter attached. I will be in touch to arrange a meeting for later this week between Pfizer, Government of Georgia and Covax to discuss further.

Best wishes

Rosie

Rosie Grieves

Senior Manager Country Engagement

Mobile: +44 7849 574189

Web: gavi.org

NOTICE: This email, including any attachments to it, may be confidential and does not create any binding contract on behalf of Gavi or its partners.

If this email was sent to you in error, please notify the send